vericel-brochure-request-950x250

Rapid detection of contaminants is essential for cell therapy products with short shelf lives. Integrating quality into the process through lot segregation, raw material qualification, environmental control, personnel training, and detailed procedures is critical because final results for conventional microbiological tests may not be available prior to product release or patient administration. EMA approval of the MACI MAA in 2013 followed by US FDA BLA approval in 2016 included three RMM product release assays for sterility, endotoxin, and mycoplasma. Read about Vericel Corporation and their journey to obtain approval of three rapid microbiological methods for MACI product release.

*
 Have a sales representative contact me
 Request a Quote, Demo or Sample
 No follow up
Fill in the form to access this article.

(*Indicates a mandatory field)

*
*
*
*
 
*